RxDoctor Payments Data

Michael Cannon, MD

Family Medicine · Chesterfield, MONPI 1154348761

Payments from drug & device makers

$476in general payments, 2019–2025

Across 24 payments — averaging $19.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$132
  • Tosoh Bioscience, Inc.$112
  • Abbott$77
  • AbbVie$67
  • Johnson & Johnson$57
  • Pfizer$19
  • plus $12 from 1 others

What the payments were for

  • Food & beverage$36476%
  • Gifts$11224%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$476 in reported general payments places this provider in the 50th percentile of 2,203 family medicine providers in Missouri.

See all family medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$74,190
Medicare patients
203
Services billed
889

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban93$100,992
TrulicityDulaglutide60$79,785
OzempicSemaglutide30$45,684
XareltoRivaroxaban30$35,571
JardianceEmpagliflozin22$29,547
JanuviaSitagliptin Phosphate14$22,680
MyrbetriqMirabegron26$18,182
ArexvyRsvpref3 Antigen/As01e/Pf54$14,111
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog24$7,823
Spiriva HandihalerTiotropium Bromide12$5,989
Spiriva RespimatTiotropium Bromide11$5,893
Arnuity ElliptaFluticasone Furoate12$4,999
GemtesaVibegron11$4,808
Lantus SolostarInsulin Glargine,hum.Rec.Anlog37$4,597
SynthroidLevothyroxine Sodium53$3,976

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$19$100,99293 claims
Lilly USA, LLCTrulicity$12$79,78560 claims
Johnson & JohnsonXarelto$57$35,57130 claims
AbbVieSynthroid$67$3,97653 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 2,203 family medicine providers in Missouri.

Other family medicine in Chesterfield

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →